PipelineReview.com7h
Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine
LONDON, UK I3, 2024 I Vicebio Ltd ("Vicebio"), a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral ...
PipelineReview.com7h
Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)
NEW HAVEN, CT, USA I3, 2024 I Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), today announced positive topline results from ...
PipelineReview.com7h
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium
SYDNEY, Australia I September 23, 2024 I Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the ...
PipelineReview.com7h
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
In preclinical studies ARO-INHBE reduced body weight and fat mass with a novel mechanism of action that may preserve lean muscle mass compared to currently ...
PipelineReview.com14h
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
MELBOURNE, Australia, INDIANAPOLIS,IN and LAKE MARY, FL, USA I September 23, 2024 I Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RLS (USA) Inc. (RLS, RLS Radiopharmacies), ...
PipelineReview.com16h
Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
MARSEILLE, France I3, 2024 I Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S Food ...
PipelineReview.com3d
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
PARIS, France I September 20, 2024 I Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the European Commission has conditionally approved Iqirvo ® (elafibranor) 80mg tablets for the treatment of ...
PipelineReview.com3d
CD (Suzhou) Biopharma Announces FDA Clearance for Phase I Clinical Trial of CD-001
SUZHOU, China I September 20, 2024 I CD (Suzhou) Biopharma has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application of CD-001, ...
PipelineReview.com3d
FDA Approves First Treatment for Niemann-Pick Disease, Type C
SILVER SPRING, MD, USA I September 20, 2024 I Today, the U.S. Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Niemann-Pick disease, type C (NPC).
PipelineReview.com3d
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
NEW YORK, NY, USA & MAINZ, Germany I September 20, 2024 I Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for ...